Cerus Corporation to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference.CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) today announced that Claes Glassell, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , William J. Dawson, vice president, finance and CFO See Chief Financial Officer. , and David N. Cook, vice president of research and development, will present on Wednesday, October 27, 2004, at 11:50 a.m. Eastern Time during the Rodman and Renshaw Techvest 6th Annual Healthcare Conference. Interested parties can access a live or archived Internet broadcast of the presentation at http://www.wsw.com/webcast/rrshq4/cers. The presentation will be archived for 90 days. About Cerus Cerus Corporation is developing novel technologies to provide safer and more effective therapeutic options to patients in areas with substantial unmet medical needs, particularly within the fields of cancer, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and blood safety. The Concord, California-based company is combining its proprietary vector technologies with public domain and proprietary antigens to develop new therapies for cancer and infectious disease. Cerus has two therapeutic cancer vaccine products in development using its Listeria Listeria /Lis·te·ria/ (lis-ter´e-ah) a genus of gram-negative bacteria (family Corynebacterium); L. monocyto´genes causes listeriosis. Lis·te·ri·a n. vector technology, one in collaboration with MedImmune, Inc. and the other with Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. . Cerus is also collaborating with subsidiaries of Baxter International Inc. on the INTERCEPT Blood System, which is designed to enhance the safety of donated blood components by inactivating viruses, bacteria and other pathogens. The INTERCEPT Blood System is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System for platelets is approved for use in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community and Canada. Helinx is a trademark of Cerus Corporation. Baxter and INTERCEPT are trademarks of Baxter International Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion